Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2007 February;55(1) > Minerva Cardioangiologica 2007 February;55(1):83-94

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

REVIEWS  INNOVATIONS IN ENDOVASCULAR INTERVENTIONS


Minerva Cardioangiologica 2007 February;55(1):83-94

language: English

Advances in the percutaneous treatment of aortic and mitral valve disease

Rajagopal V., Kapadia S. R., Tuzcu E. M.

Department of Cardiovascular Medicine Cleveland Clinic Foundation Cleveland, OH, USA


PDF  


The healthcare burden of valvular heart disease continues to increase as our population ages. Because of advances in operative techniques and cardiac anesthesiology, surgery has excellent safety and durability for many patients, and surgery remains the gold standard for treating valvular heart disease. Because many patients have comorbidities that increase operative risk, interest in catheter-based valve repair and replacement has grown. Early human experience with aortic stent-valve prostheses has been quite encouraging. For mitral regurgitation, percutaneous annuloplasty and leaflet repair are being developed by numerous companies, and early human studies have demonstrated feasibility of percutaneous repair. Continuing advances in technology and experience promise to expand the role of percutaneous repair and replacement in the treatment of valvular heart disease. Ongoing trials will help define long-term durability and safety, along with appropriate patient selection for percutaneous treatment.

top of page

Publication History

Cite this article as

Corresponding author e-mail